Caris Life Sciences Partners with Everlywell to Launch Cancer Screening

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Jan 12 2026

0mins

Caris Life Sciences announced a partnership with Everlywell, a digital health company. Caris and Everlywell are partnering to launch Caris Detect, Caris' forthcoming Multi-Cancer Early Detection blood-based screening assay, through Everlywell's platform. Caris Detect utilizes comprehensive whole genome sequencing technology to identify multiple cancer types by analyzing molecular signals circulating in the bloodstream. Caris expects to launch the Caris Detect assay in the first half of 2026.

CAI

$25.55+Infinity%1D

Analyst Views on CAI

Wall Street analysts forecast CAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAI is 37.60 USD with a low forecast of 30.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Analyst Rating

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 25.480

Low

30.00

Averages

37.60

High

45.00

Current: 25.480

Low

30.00

Averages

37.60

High

45.00

Citi

Buy

upgrade

$34 -> $42

2025-08-13

Reason

Citi

Price Target

$34 -> $42

AI Analysis

2025-08-13

upgrade

Buy

Reason

Citi raised the firm's price target on Caris Life Sciences to $42 from $34 and keeps a Buy rating on the shares. The firm views Caris Life's first quarter as a public company as strong and lifted estimates post the print.

BTIG

Mark Massaro

Buy

maintain

$38 -> $45

2025-08-13

Reason

BTIG

Mark Massaro

Price Target

$38 -> $45

2025-08-13

maintain

Buy

Reason

BTIG analyst Mark Massaro raised the firm's price target on Caris Life Sciences to $45 from $38 and keeps a Buy rating on the shares. The company reported a nearly unprecedented 31% revenue beat in its first quarter as a public company, driven primarily by higher-than-expected mix contribution from its MI Cancer Seek CDx, which carries a premium CMS rate of $8,455, the analyst tells investors in a research note. Caris seems to be holding firmly onto its market leadership in tissue therapy selection and estimates that the therapy selection market stands at just 30% overall penetration, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CAI

Unlock Now

JPMorgan

Rachel Vatnsdal

Overweight

initiated

$31

2025-07-14

Reason

JPMorgan

Rachel Vatnsdal

Price Target

$31

2025-07-14

initiated

Overweight

Reason

JPMorgan analyst Rachel Vatnsdal initiated coverage of Caris Life Sciences with an Overweight rating and $31 price target. The firm says Caris is a leading diagnostics company focused on enabling precision medicine. The company's whole exome sequencing and whole transcriptome sequencing technology targets significantly more genes than competitive assays, the analyst tells investors in a research note. JPMorgan believes Caris recently reached an inflection point with FDA approval of its tissue-based therapy selection assay.

Guggenheim

Buy

initiated

$32

2025-07-14

Reason

Guggenheim

Price Target

$32

2025-07-14

initiated

Buy

Reason

Guggenheim initiated coverage of Caris Life Sciences with a Buy rating and $32 price target. The firm says Caris is a precision diagnostics company offering clinical testing services in therapy selection indications and biopharma services through its assay menu and database. The company's therapy selection platform and large database will continue to be "important differentiations from competitors and to drive long-term growth," the analyst tells investors in a research note.

About CAI

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.